scholarly journals Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey

2017 ◽  
Vol 28 ◽  
pp. v557-v558
Author(s):  
G. Beinse ◽  
D. Reitter ◽  
L. Segaux ◽  
M. Carvalho-Verlinde ◽  
C. Tournigand ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Older Patients ◽  
Potential Drug ◽  
Patients With Cancer

scholarly journals Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy

2014 ◽  
Vol 5 (3) ◽  
pp. 307-314 ◽  
Author(s):  
Mihaela A. Popa ◽  
Kristie J. Wallace ◽  
Antonella Brunello ◽  
Martine Extermann ◽  
Lodovico Balducci
Keyword(s):  
Drug Interactions ◽  
Older Patients ◽  
Potential Drug ◽  
Patients With Cancer

Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort

2020 ◽  
Vol 11 (4) ◽  
pp. 586-592 ◽  
Author(s):  
Guillaume Beinse ◽  
Delphine Reitter ◽  
Lauriane Segaux ◽  
Muriel Carvahlo-Verlinde ◽  
Benoit Rousseau ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cancer Patients ◽  
Older Patients ◽  
Potential Drug ◽  
Elderly Cancer Patients ◽  
Patients With Cancer

scholarly journals Potential interactions between antineoplastic agents and medicines used to treat Covid-19

2021 ◽  
pp. 107815522110404
Author(s):  
Mario Jorge Sobreira da Silva ◽  
Claudia Garcia Serpa Osorio-de-Castro ◽  
Rafael Duarte Paes ◽  
Christopher Lucas Negrete ◽  
Elizangela Eugênio ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Patient Outcomes ◽  
Antineoplastic Agents ◽  
Kinase Inhibitors ◽  
Antineoplastic Drugs ◽  
Potential Drug ◽  
Pharmacological Interventions ◽  
Patients With Cancer ◽  
Risks And Benefits ◽  
Potential Interactions

Introduction Cancer patients with Covid-19 are exposed to treatment combinations that can potentially result in interactions that adversely affect patient outcomes. This study aimed to identify potential drug–drug interactions between antineoplastic agents and medicines used to treat Covid-19. Methods We conducted a search for potential interactions between 201 antineoplastic agents and 26 medicines used to treat Covid-19 on the Lexicomp® and Micromedex® databases. The following data were extracted: interaction severity (“major” and “contraindicated”) and interaction effects (pharmacokinetic and pharmacodynamic). We also sought to identify the therapeutic indication of the antineoplastic drugs involved in the potential drug–drug interactions. Results A total of 388 “major” or “contraindicated” drug–drug interactions were detected. Eight drugs or combinations (baricitinib, lopinavir/ritonavir, atazanavir, darunavir, azithromycin, chloroquine, hydroxychloroquine, and sirolimus) accounted for 91.5% of these interactions. The class of antineoplastic agents with the greatest potential for interaction was tyrosine kinase inhibitors (accounting for 46.4% of all interactions). The findings show that atazanavir, baricitinib, and lopinavir/ritonavir can affect the treatment of all common types of cancer. The most common pharmacokinetic effect of the potential drug–drug interactions was increased plasma concentration of the antineoplastic medicine (39.4%). Conclusions Covid-19 is a recent disease and pharmacological interventions are undergoing constant modification. This study identified a considerable number of potential drug–drug interactions. In view of the vulnerability of patients with cancer, it is vital that health professionals carefully assess the risks and benefits of drug combinations.

Prevalence of alcohol-drug interactions in community-dwelling older patients with polypharmacy

2021 ◽  
Vol 36 (4) ◽  
pp. 281-288
Author(s):  
Santina L. Gorsen ◽  
Els Mehuys ◽  
Leen De Bolle ◽  
Koen Boussery ◽  
Eline Tommelein
Keyword(s):  
Older Adults ◽  
Drug Interactions ◽  
Older Patients ◽  
Medication Use ◽  
Community Dwelling ◽  
Sample Population ◽  
Potential Drug ◽  
Additional Information ◽  
Drug Substances ◽  
Concurrent Use

Abstract Objectives Alcohol and medication use are increasingly prevalent in the older population. Concurrent use of alcohol and alcohol-interactive (AI) medication can lead to significant adverse consequences. Methods Three reference works were used to create an explicit list of drug substances for which information about the interaction with alcohol was available in at least one of them. Additional information was extracted from the Summary of Product Characteristics (SPC). The first aim was to generate a list of 256 substances with standardized advice regarding the concurrent use of each drug with alcohol. The second aim was to observe the prevalence of potential drug–alcohol-interactions. The list was applied to a database containing information about alcohol and medication use of 1,016 community-dwelling older patients (≥70 years) with polypharmacy. Results About half of the sample population reported to consume alcohol at least once a week. Around 22% were classified as frequent drinkers (5–7 days/week) and 11% as heavier drinkers (>7 units/week). Ninety-three percent alcohol consumers in our sample took at least one chronic drug that potentially interacts with alcohol and 42% used at least one chronic drug for which alcohol use is considered contraindicated. Conclusions We developed an explicit list of potentially drug–alcohol-interactions in older adults, with standardized handling advice. We observed that prevalence of potential drug–alcohol-interactions is substantial in community-dwelling older patients with polypharmacy.

Prevalence of alcohol-drug interactions in community-dwelling older patients with polypharmacy

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Santina L. Gorsen ◽  
Els Mehuys ◽  
Leen De Bolle ◽  
Koen Boussery ◽  
Eline Tommelein
Keyword(s):  
Older Adults ◽  
Drug Interactions ◽  
Older Patients ◽  
Medication Use ◽  
Community Dwelling ◽  
Sample Population ◽  
Potential Drug ◽  
Additional Information ◽  
Drug Substances ◽  
Concurrent Use

Abstract Objectives Alcohol and medication use are increasingly prevalent in the older population. Concurrent use of alcohol and alcohol-interactive (AI) medication can lead to significant adverse consequences. Methods Three reference works were used to create an explicit list of drug substances for which information about the interaction with alcohol was available in at least one of them. Additional information was extracted from the Summary of Product Characteristics (SPC). The first aim was to generate a list of 256 substances with standardized advice regarding the concurrent use of each drug with alcohol. The second aim was to observe the prevalence of potential drug–alcohol-interactions. The list was applied to a database containing information about alcohol and medication use of 1,016 community-dwelling older patients (≥70 years) with polypharmacy. Results About half of the sample population reported to consume alcohol at least once a week. Around 22% were classified as frequent drinkers (5–7 days/week) and 11% as heavier drinkers (>7 units/week). Ninety-three percent alcohol consumers in our sample took at least one chronic drug that potentially interacts with alcohol and 42% used at least one chronic drug for which alcohol use is considered contraindicated. Conclusions We developed an explicit list of potentially drug–alcohol-interactions in older adults, with standardized handling advice. We observed that prevalence of potential drug–alcohol-interactions is substantial in community-dwelling older patients with polypharmacy.

scholarly journals Nutraceuticals for Smart Aging and Potential Drug Interactions

2021 ◽  
Vol 5 (1) ◽  
pp. 4
Author(s):  
Maria D. Auxtero ◽  
Mário Abade ◽  
Susana Chalante ◽  
Bianca Silva ◽  
Ana I. Fernandes
Keyword(s):  
Drug Interactions ◽  
Older Patients ◽  
Age Group ◽  
Potential Drug ◽  
Cognitive Enhancers

The use of nutraceuticals as cognitive enhancers is on the rise and may be especially problematic in polymedicated older patients. The potential of interaction of these products with drugs commonly prescribed to this age group is evaluated in this work, by identification of mutual targets (enzymes, transporters and receptors).

OTC Orlistat Poses Potential Drug Interactions

2006 ◽  
Vol 36 (4) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Drug Interactions ◽  
Potential Drug
Sign in / Sign up

Export Citation Format

Share Document